INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 48 filers reported holding INOZYME PHARMA INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $5,602,000 | -56.4% | 2,090,436 | -22.5% | 0.11% | -57.7% |
| Q2 2022 | $12,862,000 | +34.1% | 2,696,372 | +15.0% | 0.26% | +23.8% |
| Q1 2022 | $9,590,000 | -40.0% | 2,344,786 | 0.0% | 0.21% | -36.1% |
| Q4 2021 | $15,991,000 | -41.2% | 2,344,786 | 0.0% | 0.34% | -36.8% |
| Q3 2021 | $27,176,000 | -26.8% | 2,344,786 | +7.6% | 0.53% | -19.7% |
| Q2 2021 | $37,130,000 | -4.5% | 2,178,985 | +10.9% | 0.66% | -19.2% |
| Q1 2021 | $38,887,000 | +63.8% | 1,964,000 | +70.7% | 0.82% | +74.2% |
| Q4 2020 | $23,742,000 | -21.5% | 1,150,299 | 0.0% | 0.47% | -36.3% |
| Q3 2020 | $30,241,000 | – | 1,150,299 | – | 0.74% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $27,113,000 | 10.69% |
| Burrage Capital Management LLC | 242,517 | $4,132,000 | 4.14% |
| CHI Advisors LLC | 927,264 | $15,801,000 | 3.68% |
| Sofinnova Investments, Inc. | 2,028,308 | $34,562,000 | 1.99% |
| Novo Holdings A/S | 1,867,706 | $31,826,000 | 1.41% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,178,985 | $37,130,000 | 0.66% |
| RA Capital Management | 2,003,653 | $34,142,000 | 0.55% |
| NEA Management Company, LLC | 2,444,379 | $41,652,000 | 0.54% |
| Rock Springs Capital Management LP | 840,272 | $14,318,000 | 0.28% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 365,172 | $6,223,000 | 0.09% |